First Real-World Data for Leqembi Reveals Implementation Challenges in Alzheimer's Treatment
核心洞察
Initial real-world data from specialized clinical practices highlights significant operational challenges in Leqembi implementation, with one case study showing a 20-month delay between initial patient presentation and treatment initiation.
Experts emphasize the need for broader real-world insights from diverse healthcare settings to improve implementation of anti-amyloid beta (搜索) monoclonal antibodies in Alzheimer's disease (搜索) management.
Questions persist regarding Leqembi's maintenance dosing protocol, which lacks a specified treatment endpoint, contrasting with Kisunla's recommendation to consider discontinuation after sufficient amyloid clearance.
The first real-world data for Eisai and Biogen's Leqembi (lecanemab) presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2025) has highlighted significant operational challenges in implementing this novel Alzheimer's treatment in clinical practice.
Early experiences from specialized private clinical practices reveal concerning timelines in the patient journey. In one U.S. case study presented during the symposium, researchers documented a 20-month delay between the patient's initial presentation to primary care and the actual initiation of Leqembi therapy—a substantial waiting period for patients with a progressive neurodegenerative condition.
Implementation Barriers in Different Healthcare Settings
Experts at the conference cautioned that the implementation challenges observed in specialized private practices likely underrepresent the difficulties that larger public healthcare systems will face. The complex infrastructure required for proper patient screening, monitoring, and administration of anti-amyloid beta (搜索) monoclonal antibodies (mAbs) presents substantial hurdles for broader adoption.
"The experience in larger public healthcare services is likely to be different," noted one presenter, highlighting concerns about scalability and accessibility of these treatments across diverse healthcare settings.
Need for Diverse Real-World Evidence
Clinicians and researchers emphasized that further real-world insights from more varied clinical practices and broader patient populations will be critical to improve implementation strategies for anti-amyloid beta (搜索) mAbs like Leqembi.
The current data primarily reflects experiences in controlled environments with carefully selected patients. As these therapies become more widely available, understanding their performance in diverse healthcare settings with more heterogeneous patient populations will be essential for optimizing treatment protocols and patient selection criteria.
Unanswered Questions About Treatment Duration
The symposium also highlighted important questions regarding the optimal duration of Leqembi therapy. Unlike Eli Lilly's Kisunla (donanemab), which specifies considering treatment discontinuation once sufficient amyloid clearance is achieved, Leqembi's current labeling does not specify a treatment endpoint, potentially committing patients to indefinite maintenance dosing.
This distinction raises important considerations about long-term treatment strategies, healthcare resource utilization, and cumulative safety risks with extended therapy.
Safety Profile Monitoring
Longer-term real-world data will be crucial for continued understanding of the safety profile of anti-amyloid beta (搜索) mAbs as their adoption increases. While clinical trials have provided important safety information, the controlled nature of these studies may not fully capture the range of adverse events that could emerge in broader clinical use.
Monitoring for amyloid-related imaging abnormalities (ARIA (搜索)), including ARIA-E (edema) and ARIA-H (hemorrhage), remains a particular focus as these treatments expand to patients who may have different risk profiles than those included in pivotal trials.
Future Directions
As the field moves forward with these first-generation disease-modifying therapies for Alzheimer's disease (搜索), stakeholders acknowledge that optimizing their implementation will require continued collection and analysis of real-world evidence.
Healthcare systems, payers, and clinicians will need to collaborate to develop streamlined pathways that reduce delays in diagnosis and treatment initiation while maintaining appropriate safety monitoring protocols.
The insights gained from these early real-world experiences with Leqembi will likely inform not only its ongoing clinical use but also implementation strategies for future Alzheimer's disease (搜索) treatments as they enter the market.